Phytomedics Inc.

Phytomedics Inc. has a broad and truly innovative proprietary technology platform that enables it to discover, develop and manufacture novel botanical drugs, recombinant proteins and nutraceuticals. This platform, licensed from Rutgers University, overcomes major technological and economic obstacles to developing a new generation of efficacious, safe and standardized botanical therapeutics for humans. It also allows rapid and cost effective production of recombinant therapeutic proteins in plants.

Activity:

- Licensing & Business Development
- Manufacturing
- Research & Development

Product / Technology type(s) covered:

- Bio
- Cosmoceuticals
- Curative
- Enzymes
- NCE (new chemical entities)
- OTC (over the counter drugs)
- Pharmaceuticals / Therapeutics
- Phyto
- Nutritionals / Vitamins
- Prescription drugs (Rx)
- Preventive
- Proteins
- Technology

Therapeutic targets:

- Aging
- AIDS
- Allergy
- Alzheimer's Disease
- Arthritis / Rheumato
- Asthma
- Cancer
- Cardiovascular
- Central nervous system
- Cough / Cold
- Dermatology
- Diabetes
- Epidemiology
- Gastrointestinal
- Genetics
- Geriatrics
- Hematology
- Infectious Diseases
- Men's Health
- Mental Health
- Neurology
- Obesity
- Oncology
- Ophthalmology
- Orthopedics
- Pain
- Pediatrics
- Radiology
- Reproductive Health
- Respiratory Medicine
- Stroke
- Surgery
- Tonics
- Transplant
- Urology
- Women's Health

Markets Covered

a. HeadQuarter: United States of America

b. Continent(s) active: North America , Europe , Far East , Asia , Central/South America , Near/Middle East , Australia/New-Zealand , Africa

c. Countries active: U.S.A, U.K., Germany, France, Japan, Hong Kong, Taiwan, South Korea, Italy, Brazil

Corporate data:

Number of Employees: 25

Turnover:

Amount:	Year:	Currency:
2,000,000	2001	US Dollar

Year founded: 1996